Biocept (BIOC) Misses Q2 EPS by 14c

Biocept (NASDAQ: BIOC) reported Q2 EPS of ($0.14), $0.14 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $12 million versus the consensus estimate of $17.76 million.

For earnings history and earnings-related data on Biocept (BIOC) click here.

You May Also Be Interested In

• Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands'
• Delta Air Lines (DAL) Tops Q2 EPS by 3c, Beats on Revenue; Offers Guidance
• Barclays upgrades CubeSmart, cuts Public Storage on relative valuation